⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TOVX News
Theriva Biologics, Inc.
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2025
globenewswire.com
TOVX
Form 8-K
sec.gov
TOVX
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
globenewswire.com
TOVX
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
globenewswire.com
TOVX
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum
globenewswire.com
TRNR
TOVX
ELAB
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
globenewswire.com
TOVX
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
globenewswire.com
TOVX
Theriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásico
globenewswire.com
TOVX
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
globenewswire.com
TOVX
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2025
globenewswire.com
TOVX